Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial Meeting Abstract
| Authors: | Rini, B. I.; Escudier, B.; Tomczak, P.; Kaprin, A.; Hutson, T. E.; Szczylik, C.; Tarazi, J. C.; Rosbrook, B.; Kim, S.; Motzer, R. J. |
| Abstract Title: | Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial |
| Meeting Title: | 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 29 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2011 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2011-05-20 |
| Language: | English |
| ACCESSION: | WOS:000208880300545 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2011.29.15_suppl.4503 |
| Notes: | Meeting Abstract: 4503 -- Source: Wos |
